2 edition of Biopharmacy of sustained release theophylline in asthmatic children. found in the catalog.
Biopharmacy of sustained release theophylline in asthmatic children.
1982 in Bradford .
Written in English
M.Pharm. dissertation. Typescript.
The Consistency of Theophylline Absorption from a Sustained-Release Formulation in Asthmatic Children. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy , 8 . • Approximately 7% of the population. • Asthma is the most common chronic disease among children. • Prevalence rate is highest in children 5–17 years at %. • Asthma accounts for % of all ambulatory care visits. • Children younger than 15 years of age have the highest rate of hospitalization at 31 population. Book Reviews. The Handbook of Physiology: The Respiratory System; Circulation and Nonrespiratory Functions, Volume 1 Sustained Release Theophylline: A Biopharmaceutical Challenge to a Clinical Need, Sustained Release Theophylline: In the Treatment of Crao, Sustained Release Theophylline: And Nocturnal Asthma. Ramsay LE, Mackay A, Eppel ML, Oliver JS. Oral sustained release aminophylline in medical inpatients: factors related to toxicity and plasma theophylline concentrations. Br J .
COVID Resources. Reliable information about the coronavirus (COVID) is available from the World Health Organization (current situation, international travel).Numerous and frequently-updated resource results are available from this ’s WebJunction has pulled together information and resources to assist library staff as they consider how to handle coronavirus.
DISCUSSION The present study is the first to report on the phar- macokinetics of sustained-release theophylline in in- fants and young children. The results indicate that Somophyllin administered every 12 hr can main- tain therapeutic concentrations of theophylline in about 45% of asthmatic children under 6 yr of by: Twice daily sustained release theophylline gave satisfactory steady serum theophylline concentrations in asthmatic children aged 7 to 14 years.
The children showed improvement in symptoms, less frequent waking at night, reduced use of beta agonist inhalers, and improved early morning peak flows while being treated with this by: Twenty asthmatic children aged years were enrolled in an open, sequential crossover, clinical comparison of long-acting theophylline formulations.
The efficacy and safety of sustained-released theophylline (SR) preparations taken t.i.d. and a controlled-release theophylline (CR) formulation administered b.i.d. were compared in children Author: Sandra M.
Gawchik, Elaine George, W.A. Spiegel, Anthony R. Rooklin. Abstract. 1 The in vitro characteristics (dissolution rate) of a sustained release theophylline preparation (Theo-Dur were first measured in acid medium (pH = 1) for 2 h and after that in a phosphate buffer (pH = ) for 6 h.
2 The tablets released more than 95% of the active ingredient within 5 h at a rate of approximately 11% of the dose per hour at pH = 1 and about 18% at pH = 3 Dose Cited by: The bioequivalency of two sustained-release theophylline formulations (SRT), Theotrim and Theodur, was studied in the steady state in asthmatic children, using a double-blind crossover design.
Ten children, aged 7–14 (mean ) years, were treated for 2 weeks, with identical doses (mean 16 mg/kg•day) of either Theotrim or Theodur tablets. 2. Kelly HW, and Murphy S: Serum theophylline levels in asthmatic children receiving sustained release theophylline tablets, Am J Hosp Pharm3.
Bell T, and Bigley J: Sustained release theophylline therapy for chronic childhood asthma, Pediatrics4. A sustained-release preparation of theophylline was administered in individually titrated doses, producing a mean plasma theophylline concentration of about 8 micrograms/ml.
Statistically significant improvements were found during the theophylline treatment in symptom score, consumption of beta2 stimulants in aerosol form, and morning peak. The bioequivalency of two sustained-release theophylline formulations (SRT), Theotrim and Theodur, was studied in the steady state in asthmatic children, using a double-blind crossover design.
Ten. Theophylline has emerged as a major prophylactic agent for controlling the symptoms of chronic asthma, but it provides little if any relief of pulmonary symptoms caused by irreversible chronic airways obstruction.
Although in vitro it inhibits phosphodiesterase and antagonizes adenosine receptors, theophylline's mechanism of action in asthma is unknown. Often, 10 to 2 µg/ml is used as the. Young children, being rapid theophylline metabolizers, are thought not to be candidates for such therapy.
We conducted a sequential crossover, nonblinded, nonrandomized evaluation of UN in 24 children (6–12 years of age) with chronic asthma clinically controlled while receiving bid. Three hundred and eighty-three asthmatic patients receiving sustained release theophylline – mg/day entered the study and were randomised to receive either salmeterol/fluticasone propionate combination (SFC) 50 μg/ μg+1 placebo tablet, fluticasone propionate μg+1 sustained release theophylline mg (SR-T+FP), twice daily for.
Theophylline doses are based on weight in children. Your child's dose needs may change if the child gains or loses weight. This medicine can affect the results of certain medical tests.
Tell any doctor who treats you that you are using theophylline. Store at room temperature away from moisture, heat, and light. A hour sustained-release preparation of theophylline was compared to a hour preparation in 14 patients who while on treatment had mild to moderate asthma.
The Cmax-to-Cmin differences were greater with the once-daily preparation than with the twice-daily preparation, and this was associated with small but significant changes in pulmonary. The relative bioavailability of a controlled-release theophylline formulation after multiple doses.
Immunol. Allerg. Pract., 3 () Lonnenholm, G., Foucard, T. and Lindstrom, B., Treatment of chronic asthma in children with a sustained-release pre- paration of theophyUine in addition to beta-stimulating agents. Eur. Respir. Dis. This study investigated whether theophylline administration has an impact on serum levels of interleukin (IL)-4 and IL-5 in asthmatic asymptomatic patients aged 30 yrs (mean sem.
Fifty two preschool children with asthma were given a recommended regimen of slow release theophylline. There was wide variation in the metabolism of theophylline.
The approach adopted gave disappointing results. Nine children did not comply, and 16 stopped treatment because of side effects. Sustained-release theophylline is a mild to moderate bronchodilator used as an alternative, although not preferred, adjunctive therapy with inhaled corticosteroids.
Red Book. Montvale, N.J. Oral loading dosage (dosage is expressed as theophylline - NOTE- do not use sustained-release dosage forms) Adults, Adolescents, and Children 5 mg/kg PO loading dose using an immediate-release product in a patient who has received no theophylline in the previous 24 hours will produce an average peak serum theophylline concentration of 10 mcg/mL.
Oral theophylline is a potential alternative option (not preferred) in adolescents and adults as a long-term control medication in mild asthma or as an add-on long-term control medication in moderate to severe asthma; however, a stepwise approach using inhaled corticosteroids (+/- inhaled long-acting beta agonists depending on asthma severity.
Theophylline has emerged as a major prophylactic agent for controlling the symptoms of chronic asthma, but it provides little if any relief of pulmonary symptoms caused by irreversible chronic. Extended Release Tablets ( or mg): Stabilized patients taking immediate or controlled release theophylline: One tablet orally once a day in the morning or evening (on a mg for mg basis with the previous dose) Comments: Theophylline distributes poorly into body fat; mg/kg doses should use ideal body weight for calculations.
Birkett DJ, Coulthard KP, Lines D, Grgurinovich N. Circadian variation in the absorption of three sustained release theophylline products in asthmatic children and the effect of food on absorption of Somophyllin-CRT. Br J Clin Pract Suppl. ; – Busse WW, Bush RK.
Expert panel report 2. NIH/NHLBI publication no. Washington DC:NIH 3. Vichyanond P, Jirapongsananuruk O, Visitsuntorn N, Tuchinda M.
Prevalence of asthma, rhinitis, and eczema in children from the Bangkok area using the ISAAC (International study for asthma and allergy in children) questionnaires.
J Med Assoc Thai ; 4. release theophylline on asthma induced by ultason- pressor T-cells in asthmatic children by theophylline. treatment. Clin Allergy ; sodium and sustained release theophylline in childhood. Low dose ICS plus sustained release theophylline. Sustained release theophylline *ICS = Inhaled Glucocorticosteroids ** = Receptor antagonist or synthesis inhibitors Alternative reliever treatments include inhaled anticholinergics, short acting oral beta 2 agonists, some long acting beta 2 agonists and short acting theophylline.
Theophylline, also known as 1,3-dimethylxanthine, is a phosphodiesterase inhibiting drug used in therapy for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma under a variety of brand names.
As a member of the xanthine family, it bears structural and pharmacological similarity to theobromine and caffeine, and is readily found in nature, being present in. Asthma currently affects nearly 5 million children in the United States—more than 5 percent of the population younger than 18 years.1 In children.
Children Related Information N/A cyclic AMP accumulation in the cell. This cause bronchodialatation, cardiac stimulation and vasodilatation. This drug release calcium from sarcoplasmic reticulam, especially in cardiac muscles and results increased cardiac muscle contraction.
Indications for Theophylline 1. Asthma 2. Chronic obstructive. Patients were grouped by age, 1–4 years, 4–7 years, and 7–10 years; and for each patient the theophylline dose, therapeutic response, and side effects were recorded. Thirty-one percent (31%) of the youngest age group experienced significant adverse central nervous system reactions to low doses of sustained-release theophylline.
(eg, leukotriene receptor antagonist [LTRA], sustained-release theophylline [SRT]) to low-dose ICSs. (Fluticasone furoate and mometasonearemedium-doseICS,butcanbeusedincombination at step 3 if needed per formulary.) These are described below. Regardless of which. An estimated million children have asthma, in Red book.
Montvale, N.J.: Medical Economics Data, Sustained-release theophylline to serum concentration of 5 to 15 μg per mL is an. The purpose of this study was to compare the efficacy and safety of the inhaled budesonide, sustained-release theophylline and montelukast, a leukotriene receptor antagonist, in patients with mild.
Patients with severe persistent asthma (Step 4) should be treated with inhaled corticosteroids at ≥–2, µg and long-acting β 2 ‐adrenoceptor agonists and/or sustained-release theophylline as well as long-term oral corticosteroids. SPECIAL FEATURES.
Kirk-Othmer Encyclopedia in print; The perfect companion. Ullmann's Encyclopedia of Industrial Chemistry; Online Resources Flyer: Chemical Engineering &. Dose Dependency for pharmacokinetics of theophylline and the formation of its major metabolites, 3-methylxanthine (3-MX); 1-methyluric acid (1-MU); 1,3-dimethyluric acid (DMU), were examined by administering three single oral doses (,mg) of theophylline to six healthy adult volunteers.
The serum and urine concentrations of theophylline and the metabolites in serum and urine were. Arkinstall WW, Atkins ME, White KW et al. () A comparative trial of 8 hourly and 12 hourly dosing with sustained release aminophylline in asthmatic children. In: Turner-Warwick M, Levy J (eds) New Perspectives in Theophylline Therapy.
R S Med Int Congr Symp Series 39–47 Google Scholar. Alternatives: zafirlukast, montelukast, theophylline: Severe asthma: Regularly inhaled high-dose corticosteroid + regularly inhaled long-acting β2 agonist + additional episodic asthma one of the following: leukotriene antagonist or sustained-release theophylline or oral β2 agonist or inhaled ipratropium (Step 4).
A Prospective Survey on Safety of Sustained-Release Theophylline in Treatment of Asthma and COPD Article (PDF Available) in Allergology International 55(4) January with 45 Reads. what is used for asthma as a maintenance therapy that is not used in children.
Theophylline. Why is Theophylline not used in children. There is a narrow therapuetic index, which means it borders on the chance of being toxic A patient receives a sustained release form of theophylline in the morning. When should a serum theophylline level be.
Theophylline (3-methyxanthine) has been used to treat airway diseases for over 70 years. It was originally used as a bronchodilator but the relatively high doses required are associated with frequent side effects, so its use declined as inhaled β2-agonists became more widely used.
More recently it has been shown to have anti-inflammatory effects in asthma and COPD at lower concentrations.can be classified into three types according to causative factors. Allergic or atopic asthma (sometimes called extrinsic asthma) is due to an allergy to antigens; usually the offending allergens are suspended in the air in the form of pollen, dust, smoke, automobile exhaust, or animal than half of the cases of asthma in children and young adults are of this type.In vivoand in vitroperformances of a rectally applied osmotic delivery system containing a water-soluble derivative of theophylline were compared.
The system was applied in six healthy volunteers during 72 h, and a comparison was made with two conventional dosage forms, a suppository and a solution administered orally, given once. In vitro,a perfect zero-order release rate with the osmotic.